Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A276027-2mg | 2mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $137.90 | |
A276027-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $246.90 | |
A276027-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $385.90 | |
A276027-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,088.90 |
blood-brain barrier (BBB) penetrating, specific BACE-1 inhibitor
Synonyms | Lanabecestat|1383982-64-6|AZD-3293|LY3314814|AZD3293|Lanabecestat [USAN]|X8SPJ492VF|Lanabecestat (AZD3293; LY3314814)|CHEMBL4217620|LY-3314814|Lanabecestat (USAN)|Lanabecestat(AZD3293,LY-3314814)|(1,4-trans,1'R)-4-methoxy-5''-methyl-6'-(5-(prop-1-yn-1-yl) |
---|---|
Specifications & Purity | ≥99% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of beta-secretase 1 |
Product Description | Product Describtion: |
ALogP | 3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
INCHI | InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1 |
---|---|
InChi Key | WKDNQONLGXOZRG-BOPKNSRXSA-N |
Canonical SMILES | CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2 |
Isomeric SMILES | CC#CC1=CC(=CN=C1)C2=CC3=C(CC4([C@]35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2 |
Alternate CAS | 1383984-21-1,1383982-64-6 |
PubChem CID | 67979346 |
MeSH Entry Terms | 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane-1,2'-inden-1',2'-imidazol)-4'-amine;AZD3293;lanabecestat |
Molecular Weight | 412.5 |
Enter Lot Number to search for COA:
Solubility | Soluble in DMSO and ethanol.DMSO:100 mg/mL (242.41 mM) |
---|
Starting at $241.90
1. Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M et al.. (2017) AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.. J Alzheimers Dis, 55 (3): (1039-1053). [PMID:27767991] |
2. Eketjäll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, Fälting J, Haeberlein SB, Kugler AR, Alexander RC, Cebers G. (2016) AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.. J Alzheimers Dis, 50 (4): (1109-23). [PMID:26890753] |
3. Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, Russell M, Hughes G, Haeberlein SB, Alexander RC et al.. (2017) BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.. J Clin Pharmacol, 57 (11): (1460-1471). [PMID:28618005] |